A DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer.
about
Predicting chemoinsensitivity in breast cancer with 'omics/digital pathology data fusionCellular responses of BRCA1-defective and triple-negative breast cancer cells and in vitro BRCA1 interactions induced by metallo-intercalator ruthenium(II) complexes containing chloro-substituted phenylazopyridineSilencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatinPolymorphism of UBC9 gene encoding the SUMO-E2-conjugating enzyme and breast cancer risk.Germline mutations in DNA repair genes may predict neoadjuvant therapy response in triple negative breast patients.
P2860
A DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
A DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer.
@ast
A DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer.
@en
type
label
A DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer.
@ast
A DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer.
@en
prefLabel
A DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer.
@ast
A DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer.
@en
P2860
P921
P356
P1476
A DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer.
@en
P2093
Adisorn Ratanaphan
P2860
P304
14898-14916
P356
10.3390/IJMS131114898
P407
P5008
P577
2012-11-14T00:00:00Z